Advanced search
Publication Cover
Cancer Investigation Volume 25, 2007 - Issue 1
Submit an article Journal homepage
162
Views
13
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Advanced Carcinoma of Unknown Primary Origin: A Reasonable Regimen for the Community-Based Clinic?

William Berry US Oncology Research, Inc., Houston, Texas, USA
, M.D.,
Maha Elkordy US Oncology Research, Inc., Houston, Texas, USA
, M.D.,
Mark O'Rourke US Oncology Research, Inc., Houston, Texas, USA
, M.D.,
Myrna Khan US Oncology Research, Inc., Houston, Texas, USA
, Ph.D. &
Lina Asmar US Oncology Research, Inc., Houston, Texas, USA
, Ph.D.
Pages 27-31 | Published online: 11 Jun 2009

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Anita Gothelf & Gedske Daugaard. (2010) Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncologica 49:4, pages 423-430.
Read now
George Pentheroudakis, Evangelos Briasoulis, Haralambos P. Kalofonos, Georgios Fountzilas, Theofanis Economopoulos, George Samelis, Aris Koutras, Maria Karina, Nikolaos Xiros, Epameinondas Samantas, Aristotelis Bamias & Nikolaos Pavlidis. (2008) Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncologica 47:6, pages 1148-1155.
Read now

Articles from other publishers (11)

John D. Hainsworth & Frank A. Greco. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 12 .
John D. Hainsworth & F. Anthony Greco. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 12 .
Chen-Yang Huang, Chang-Hsien Lu, Chan-Keng Yang, Hung-Chih Hsu, Yung-Chia Kuo, Wen-Kuan Huang, Jen-Shi Chen, Yung-Chang Lin, Hung Chia-Yen, Wen-Chi Shen, Pei-Hung Chang, Kun-Yun Yeh, Yu-Shin Hung & Wen-Chi Chou. (2015) A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. Medicine 94:47, pages e2135.
Crossref
Eric Yaovi Amela, Géraldine Lauridant-Philippin, Sophie Cousin, Thomas Ryckewaert, Antoine Adenis & Nicolas Penel. (2012) Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/Hematology 84:2, pages 213-223.
Crossref
. 2012. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie e1 e61 .
C. Natoli, V. Ramazzotti, O. Nappi, P. Giacomini, S. Palmeri, M. Salvatore, M. Landriscina, M. Zilli, P.G. Natali, N. Tinari & S. Iacobelli. (2011) Unknown primary tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:1, pages 13-24.
Crossref
M. Kodaira, S. Takahashi, S. Yamada, K. Ueda, Y. Mishima, K. Takeuchi, N. Yamamoto, Y. Ishikawa, M. Yokoyama, T. Saotome, Y. Terui & K. Hatake. (2010) Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Annals of Oncology 21:6, pages 1163-1167.
Crossref
Antoine Adenis, Charles Ferté & Nicolas Penel. (2009) Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Investigational New Drugs 28:2, pages 178-184.
Crossref
Vassilis Golfinopoulos, George Pentheroudakis, Georgia Salanti, Andreas D. Nearchou, John P.A. Ioannidis & Nicholas Pavlidis. (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. Cancer Treatment Reviews 35:7, pages 570-573.
Crossref
F. Anthony Greco & Nicholas Pavlidis. (2009) Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors. Seminars in Oncology 36:1, pages 65-74.
Crossref
E. Briasoulis, G. Fountzilas, A. Bamias, M. A. Dimopoulos, N. Xiros, G. Aravantinos, E. Samantas, H. Kalofonos, T. Makatsoris, N. Mylonakis, P. Papakostas, D. Skarlos, I. Varthalitis & N. Pavlidis. (2007) Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemotherapy and Pharmacology 62:2, pages 277-284.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.